SQZ
SQZ BIOTECHNOLOGIES CO (SQZ)
$0.8233.24%▲
Market is closedMarket is closed – opens on 8 PM, 06 Feb 2023
– opens on 8 PM, 06 Feb 2023
Key Stats
$0.79
Day's Range
$0.859899
$0.6538
52-Week Range
$7.61
| Returns % | |
| 1 month return | 6.56% |
| 3 month return | 70.5% |
| 1 year return | 88.86% |
| 5 year return | 93.79% |
Analyst Recommendation
based on 10 analysts ratings
Buy
90%
Buy
10%
Hold
0%
Sell
Based on 10 Wall street analysts offering stock ratings for SQZ BIOTECHNOLOGIES CO(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 1601.09%Current
$0.82
Target
$14.0
Recommendation Trend
Based on 10 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 9 | 5 | 8 |
| Hold | 1 | 0 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 24.1M |
| Book Value | $2.34 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -2.65 |
| Wall Street Target Price | 14.0 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.5 |
| Enterprise Value | 12.4M |
| Enterprise Value/Revenue | 0.58 |
| Enterprise Value/Ebitda | -0.18 |
Technicals
| Beta | 2.78 |
| 50 Day MA | 1.13 |
| 200 Day MA | 2.6 |
Institutional Holdings
Temasek Holdings Ltd.
9.37%
American International Group Inc
8.55%
683 Capital Management LLC
7.62%
Artal Group S A
5.45%
NanoDimension, Inc.
4.91%
Maverick Capital Ltd
3.63%
Company Information
SQZ Biotechnologies is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ Biotechnologies offers the unique ability to deliver multiple materials into many patient cell types to engineer what SQZ Biotechnologies believes can be an unprecedented range of potential therapeutics for a variety of diseases. SQZ Biotechnologies has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and to improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, its goal is to use the SQZ approach to establish a new paradigm for cell therapies. The Company's first therapeutic applications aim to leverage the potential to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases.
| Organization | SQZ BIOTECHNOLOGIES CO |
| Employees | 113 |
| CEO | Dr. Howard Bernstein M.D., Ph.D. |
| Industry | Health Technology |
Discover more
Frequently Asked Questions
What is SQZ BIOTECHNOLOGIES CO share price today?
Can Indians buy SQZ BIOTECHNOLOGIES CO shares?
How can I buy SQZ BIOTECHNOLOGIES CO shares from India?
Can Fractional shares of SQZ BIOTECHNOLOGIES CO be purchased?
What are the documents required to start investing in SQZ BIOTECHNOLOGIES CO stocks?
What are today’s High and Low prices of SQZ BIOTECHNOLOGIES CO?
What are today’s traded volumes of SQZ BIOTECHNOLOGIES CO?
What is today’s market capitalisation of SQZ BIOTECHNOLOGIES CO?
What is the 52 Week High and Low Range of SQZ BIOTECHNOLOGIES CO?
How much percentage SQZ BIOTECHNOLOGIES CO is down from its 52 Week High?
How much percentage SQZ BIOTECHNOLOGIES CO is up from its 52 Week low?
What are the historical returns of SQZ BIOTECHNOLOGIES CO?
Who is the Chief Executive Officer (CEO) of SQZ BIOTECHNOLOGIES CO?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*